

[54] **USE OF ORAL DIAZOXIDE FOR THE TREATMENT OF DISORDERS IN GLUCOSE METABOLISM**

[76] Inventor: **Elsa P. Paulsen**, 1115 Hilltop Rd., Charlottesville, Va. 22903

[21] Appl. No.: 936,867

[22] Filed: Aug. 27, 1992

Related U.S. Application Data

[63] Continuation of Ser. No. 669,386, Mar. 14, 1991, abandoned.

[51] Int. Cl.⁵ A61K 31/54

[52] U.S. Cl. 514/223.2; 424/9; 514/866

[58] Field of Search 514/223.2, 866

[56] **References Cited**

PUBLICATIONS

Chemical Abstracts 69:75522e (1968).

Chemical Abstracts 95:74402n (1981).

Arteriosclerosis, vol. 5, No. 4, Jul./Aug. 1985: *Impaired Glucose Tolerance*, Peter H. Bennett, National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases, Phoenix, Ariz, pp. 315-317.

J. Chron. Dis., vol. 37, No. 8, pp. 667-669, 1984, Pergamon Press Ltd., UK: *Some Thoughts on Early Detection and Intervention in Diabetes Mellitus*, Victor M. Hawthorne and Catherine C. Cowie, University of Michigan, Ann Arbor, Mich.

Diabetic Medicine, 1991, John Wiley & Sons, Ltd.: *Reactive Hypoglycaemia in Association with Disordered Islet Function and Abnormal Hepatic Glucose-6-Phosphatase Activity: Response to Diazoxide*, J. Pears et al., Ninewells Hospital Medical School, Dundee, Scotland, pp. 268-271.

Diabetes, vol. 5, No. 67, Nov./Dec. 1956; *Spontaneous Hypoglycemia as an Early Manifestation of Diabetes Mellitus*, Holbrooke S. Seltzer et al., Ann Arbor, Mich, pp. 437-440.

Diabetes Care, vol. 13, No. 5, May 1990; Stuart A. Chalew et al.: *Evidence for Elevated Glucose Threshold in Patients With Impaired Glucose Tolerance and Symptoms of Hypoglycemia During OGTT*.

New England Journal Of Medicine, vol. 318, No. 19,

May 12, 1988: *Impaired Glucose Tolerance as a Disorder of Insulin Action*, Stephen Lillioja et al.

Diabetes, vol. 36, Apr. 1987: *Prevalence of Diabetes and Impaired Glucose Tolerance and Plasma Glucose Levels in U.S. Population Aged 20-74 Yr*, Maureen I. Harris et al., pp. 523-534.

Diabetes Care, vol. 12, No. 7, Jul./Aug. 1989: *Impaired Glucose Tolerance in the U.S. Population* Maureen I. Harris, pp. 464-474.

Horm. Metabol. Res. 18 (1986) 38-41, George Thieme Verlag Stuttgart, New York, N.Y.: *Post-Receptor Insulin Resistance after Diazoxide in Non-Insulin Dependent Diabetes*, S. A. Olczak et al., pp. 38-41.

Long-term treatment with diazoxide in childhood hyperinsulinism, D. B. Grant et al. (1987).

Journal of Pediatrics, Jun. 1991, vol. 118, No. 6, pp. 906-909: *Hypertrophic cardiomyopathy after prolonged diazoxide therapy for hyperinsulinemic hypoglycemia*, Janis J. Parker et al.

(List continued on next page.)

Primary Examiner—Leonard Schenkman
Attorney, Agent, or Firm—Kenyon & Kenyon

[57]

ABSTRACT

A method is disclosed for normalizing blood glucose and insulin levels as measured by an oral glucose tolerance test in an individual exhibiting normal fasting blood glucose and insulin levels and exhibiting in an oral glucose tolerance test elevated glucose levels and at least one insulin level abnormality selected from the group consisting of a delayed insulin peak, an exaggerated insulin peak and a secondary elevated insulin peak. The method comprises administering diazoxide to the individual before ingestion of a food source in an amount effective to normalize the blood glucose and insulin levels. Diazoxide is administered in an amount from about 0.4 to about 0.8 mg/kg body weight before each meal.

9 Claims, 5 Drawing Sheets